This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy Mid-Cap AI Stock FIVN on Solid Q2 Earnings, Outlook & Valuation
by Nalak Das
FIVN posts record Q2 revenue, boosts AI growth, and trades at a steep valuation discount, making it a mid-cap AI standout.
CRM vs. NOW: Which Workflow Automation Stock Has More Upside?
by Kashvi Chandgothia
ServiceNow and Salesforce tap rising demand for AI workflows, whose platform offers more upside for investors?
Salesforce Inc. (CRM) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Salesforce.com (CRM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
PTC Inc. (PTC) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
PTC Inc. (PTC) delivered earnings and revenue surprises of +34.43% and +10.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Strong Cloud Subscription Aids PEGA's Prospects: What's More to Come?
by Zacks Equity Research
Pegasystems sees strong cloud subscription momentum ahead, driven by AI, AWS ties and legacy system migration.
NOW's Subscription Growth Picks Up: A Sign of More Upside?
by Zacks Equity Research
ServiceNow eyes $12.785B in 2025 subscription sales as AI-fueled product demand lifts long-term growth outlook.
DocuSign vs. Spotify: Which Digital Pioneer Delivers More Value?
by Shuvra Shankar Dey
DOCU's deep Microsoft and Salesforce ties, 30% free cash flow margin, and 101% net retention boost its long-term value case.
Salesforce.com (CRM) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Salesforce.com (CRM) settling at $267.39, representing a -1.06% change from its previous close.
UiPath vs. AppLovin: Which AI-Driven Tech Stock is Purchase-Worthy?
by Shuvra Shankar Dey
PATH's enterprise AI edge and valuation advantage over APP make it the smarter buy in this AI-driven tech faceoff.
Axon 2 Powers AppLovin's Explosive Growth in Mobile Advertising
by Zacks Equity Research
APP's AI engine Axon 2 has driven massive ad growth, but a lofty valuation and slowing momentum now test investor confidence.
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
by Harshit Gupta
VEEV stock climbs 36% YTD as it accelerates its shift off Salesforce, betting on Vault to power future growth in life sciences.
Salesforce.com (CRM) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the most recent trading session, Salesforce.com (CRM) closed at $267.22, indicating a +1.38% shift from the previous trading day.
Veeva vs. Salesforce: Which Life Sciences CRM Stock Is the Better Buy?
by Harshit Gupta
VEEV's split from Salesforce sets the stage for a high-stakes CRM showdown as both firms double down on life sciences innovation.
Salesforce vs. HubSpot: Which CRM Stock Is the Smarter Buy Now?
by Anirudha Bhagat
HUBS outpaces CRM in sales growth and market momentum, making it a better investment pick despite the premium.
Why Salesforce.com (CRM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors Heavily Search Salesforce Inc. (CRM): Here is What You Need to Know
by Zacks Equity Research
Salesforce.com (CRM) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pegasystems Set to Report Q2 Earnings: Is the Stock a Buy?
by Subhasish Mukherjee
PEGA's Q2 2025 results are expected to reflect cloud and GenAI momentum, aided by strong cash flow, despite forex and competitive pressures.
Is It Worth Investing in Salesforce.com (CRM) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Salesforce.com (CRM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Salesforce Bets Big on Agentforce: Can AI Agents Power Growth?
by Anirudha Bhagat
Agentforce platform hits $100 million ARR in two quarters as CRM ramps up AI agent adoption and integration.
Veeva Systems' Vault CRM Momentum Builds With Top Biopharma Adoptions
by Harshit Gupta
VEEV sees rising Vault CRM adoption among top biopharma firms, driven by new features, fueling customer migration and growth.
Has DOCU's 15% Year-to-Date Decline Created a Buying Opportunity?
by Shuvra Shankar Dey
DOCU is down 15% YTD despite solid cash flow and key integrations, but is this a reset or just a stall?
Salesforce.com (CRM) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Salesforce.com (CRM) closed at $263.97 in the latest trading session, marking a -2.57% move from the prior day.
Salesforce's Data Cloud ARR Soars 120%: Is It the Next Sales Lever?
by Anirudha Bhagat
CRM's Data Cloud tops $1B in ARR with 120% YoY growth, powering AI tools and driving major deals across its platform.
Why Investors Need to Take Advantage of These 2 Computer and Technology Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here is What to Know Beyond Why Salesforce Inc. (CRM) is a Trending Stock
by Zacks Equity Research
Salesforce.com (CRM) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.